Journal
HEMOGLOBIN
Volume 32, Issue 1-2, Pages 229-236Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/03630260701680367
Keywords
pharmacogenomics; pharmacogenetics; beta-thalassemia (thal); sickle cell disease; genotyping; single nucleotide polymorphisms (SNPs)
Categories
Funding
- NHLBI NIH HHS [5R01HL73455-02] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073455] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Individual genetic constitution is an important cause of variations in the response and tolerance to drug treatment. Single nucleotide polymorphisms (SNPs) in genes located within as well as outside the human beta-globin cluster have recently been shown to be significantly associated with Hb F increase in relation to hydroxyurea (HU) treatment in hemoglobinopathies patients. This article provides an update and discusses future challenges on the application of pharmacogenetic testing and pharmacogenomics for hemoglobinopathies therapeutics in relation to the current pharmacological treatment modalities for those disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available